Who may omit locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a failure-pattern-based strategy in the immunotherapy era.

ABSTRACT: De novo metastatic nasopharyngeal carcinoma (dmNPC) is a heterogeneous disease that exhibits variable failure patterns after first-line immunochemotherapy, complicating the decision-making for subsequent locoregional radiotherapy (LRRT). This retrospective real-world analysis enrolled 398 dmNPC patients treated with first-line immunochemotherapy with or without subsequent LRRT. We developed and validated a clinically applicable two-step risk stratification model that categorizes patients into three phenotypic subgroups based on different failure patterns. Durable responders were defined as patients likely to achieve long-term remission with immunotherapy maintenance alone. Partial responders were prone to experience isolated locoregional progression, while resistant patients had a high ris

SUBMITTER: He JR 

PROVIDER: S-EPMC12672645 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature